Safety and efficacy of anakinra in severe hidradenitis suppurativa a randomized clinical trial

JAMA Dermatology

Volumn 152, Issue 1, 2016, Pages 52-59

  Tzanetakou, Vassiliki ^a   Kanni, Theodora ^a   Giatrakou, Sophia ^a   Katoulis, Alexandros ^a   Papadavid, Evangelia ^a   Netea, Mihai G ^b   Dinarello, Charles A ^b,c   Van Der Meer, Jos W M ^b   Rigopoulos, Dimitrios ^a   Giamarellos Bourboulis, Evangelos J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 6; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DISEASE ACTIVITY SCORE; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GREECE; HUMAN; HUMAN CELL; INJECTION SITE SWELLING; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUPPURATIVE HIDRADENITIS; TREATMENT RESPONSE; VAGINA CANDIDIASIS; DRUG EFFECTS; FOLLOW UP; HIDRADENITIS SUPPURATIVA; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HIDRADENITIS SUPPURATIVA; HOSPITALS, UNIVERSITY; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84955264131     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.3903     Document Type: Article

References (30)

1. Jemec GB. Clinical practice: hidradenitis suppurativa. N Engl J Med. 2012;366(2):158-164.
2. Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-644.
3. von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144(4):809-813.
4. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59(4):596-601.
5. Kurzen H, Kurokawa I, Jemec GB, et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008;17(5):455-456.
6. Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C, et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol. 2007;156(1):51-56.
7. Dréno B, Khammari A, Brocard A, et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol. 2012; 148(2):182-186.
8. van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164(6):1292-1298.
9. Schlapbach C, Hänni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011; 65(4):790-798.
10. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205-217.
11. Blanco R, Martínez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009;145(5):580-584.
12. Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12): 846-855.
13. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2008;158(3):567-572.
14. Dinarello CA. Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med. 2011;269(1):16-28.
15. Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009;23(9):985-998.
16. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216.
17. Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149(1):211-213.
18. Kimball AB, Jemec GB, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171(6): 1434-1442.
19. Kanni T, Tzanetakou V, Savva A, et al. Compartmentalized cytokine responses in hidradenitis suppurativa. PLoS One. 2015;10(6): e0130522. doi:10.1371/journal.pone.0130522.
20. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G∗Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149-1160.
21. Teuscher N. Calculating AUC (linear and log-linear). http://learnpkpd.com/2011/04/02/calculating-auc-linear-and-log-linear/. Published April 2, 2011. Accessed September 30, 2105.
22. Leslie KS, Tripathi SV, Nguyen TV, Pauli M, Rosenblum MD. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol. 2014;70(2): 243-251.
23. Hsiao JL, Antaya RJ, Berger T, Maurer T, Shinkai K, Leslie KS. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol. 2010;146(11): 1265-1270.
24. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH): a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66(3): 409-415.
25. Zarchi K, Dufour DN, Jemec GB. Successful treatment of severe hidradenitis suppurativa with anakinra. JAMA Dermatol. 2013;149(10):1192-1194.
26. van der Zee HH, Prens EP. Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report. Dermatology. 2013;226 (2):97-100.
27. Menis D, Maroñas-Jiménez L, Delgado-Marquez AM, Postigo-Llorente C, Vanaclocha-Sebastián F. Two cases of severe hidradenitis suppurativa with failure of anakinra therapy. Br J Dermatol. 2015;172 (3):810-811.
28. Kanda N, Watanabe S. Increased serum human β-defensin-2 levels in atopic dermatitis: relationship to IL-22 and oncostatin M. Immunobiology. 2012; 217(4):436-445.
29. Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003;48(4):927-934.
30. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41(12):2196-2204.